Rent the Runway to Report Fourth Quarter and Fiscal Year 2024 Results on April 15, 2025
The financial results and live webcast, including presentation materials, will be accessible through the Investor Relations section of Rent the Runway's website at https://investors.renttherunway.com/ under the 'Events' section. To access the call through a conference line, dial 1-877-407-3982 (in the U.S.) or 1-201-493-6780 (international callers).
A replay of the conference call will be posted shortly after the call and will be available for at least fourteen days. To access the replay, dial 1-844-512-2921 (in the U.S.) or 1-412-317-6671 (international callers). The access code for the replay is 13752693.
About Rent the Runway Founded in 2009, Rent the Runway is disrupting the trillion-dollar fashion industry and changing the way women get dressed through the Closet in the Cloud. RTR's mission has remained the same since its founding: powering women to feel their best every day. Through RTR, customers can subscribe, rent items a-la-carte and shop resale from hundreds of designer brands. The Closet in the Cloud offers a wide assortment of millions of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear and ski wear. RTR has built a two-sided discovery engine, which connects deeply engaged customers and differentiated brand partners on a powerful platform built around its brand, data, logistics and technology. Under CEO and Co-Founder Jennifer Hyman's leadership, RTR has been named to CNBC's 'Disruptor 50' five times in ten years, and has been placed on Fast Company's Most Innovative Companies list four times, while Hyman herself has been named to the 'TIME 100: Most Influential People in the World" and as one of People Magazine's 'Women Changing the World."
ContactsPresspress@renttherunway.com
Investor Relationsinvestors@renttherunway.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
A 12-Stock Sane Portfolio for Crazy Times
August 4, 2025 -- (Maple Hill Syndicate) In today's higher-tariff world, where political and geopolitical clashes are harsh, you might want to take your stock portfolio's risk level down a notch. Perhaps the Sane Portfolio can be of some help. This is a theoretical portfolio, intended to be slightly on the low-risk side of the risk spectrum. It contains a dozen stocks, and I refresh the list once a year. To get in, a stock must meet seven criteria, described below. Once I choose a stock, it stays in unless it flunks one of the seven criteria. Warning! GuruFocus has detected 4 Warning Signs with BCC. Over 23 years, the Sane Portfolio has averaged an 11.2% annual return. That slightly beats the Standard & Poor's 500 Total Return Index, with an average return of 10.8%. My column results are hypothetical and shouldn't be confused with results I obtain for clients. Past performance doesn't predict the future. My list from a year ago trailed far behind the S&P. It posted a 6.9% return while the index returned 21.9%. My worst performer was Boise Cascade Co. (NYSE:BCC), down 30%. My best was Monarch Casino & Resort Inc. (NASDAQ:MCRI), up 45%. Seven Boxes To be eligible for the Sane Portfolio, a stock must satisfy seven criteria. No single criterion is especially hard, but few companies can check all seven boxes. Market value of at least $1 billion. Debt less than stockholders' equity. Return on stockholders' equity of 10% or better. Stock price less than 18 times per-share earnings. Stock price less than 3 times per-share sales. Stock price less than 3 times book value (corporate net worth per share). Five-year earnings growth averaging 5% per year or better. This year, seven Sane Portfolio companies stay on from previous years. Winning Streaks D.R. Horton Inc. (NYSE:DHI), the nation's largest homebuilder, is back for a sixth consecutive year. Many buyers can't afford a home at today's mortgage rates. So, Horton's latest year was soggy, but it has grown revenue at a 17% clip for the past decade. Back for a fifth year is Paccar Inc. (NASDAQ:PCAR), which builds heavy trucks (Kenworth and Peterbilt). The latest year has been rough. Companies have been reluctant to spend on trucks, amid tariff uncertainty. But Paccar has achieved 11% annual earnings growth in the past decade. Boise Cascade Co. (NYSE:BCC) of Boise, Idaho, which makes engineered-wood products and plywood, hangs in there for a fourth year. As noted above, this stock was a dog in the past twelve months. However, the stock looks cheap to me at about 10 times earnings. After a gain of around 30% in the past 12 months, W.R. Berkley Corp. (NYSE:WRB) returns for a third engagement. It's a commercial casualty insurance company based in Greenwich, Connecticut. Second-Timers Three companies are in the Sane Portfolio as sophomores. One is EOG Resources Inc. (NYSE:EOG), a big Houston-based oil and gas producer that emerged from the remnants of the Enron empire. Its profitability is impressive, with a 21% return on stockholders' equity. Another sophomore is Academy Sports & Outdoors Inc. (NASDAQ:ASO), a chain of sporting goods stores headquartered in Katy, Texas. I'm concerned that it gets a lot of its merchandise from China, so it may be hard-hit by tariffs. If it can stay on this roster another year, I'll be impressed. Returning, too, is Photronics Inc. (NASDAQ:PLAB), which makes photomasks using in manufacturing semiconductor chips. Profits vary from year to year, but the company, based in Brookfield, Connecticut, has shown positive earnings ten years in a row. Newbies Five companies dropped out of the Sane Portfolio, giving me five slots to fill. I'll start with Axcelis Technologies Inc. (NASDAQ:ACLS), based in Beverly, Massachusetts. Like Photronics, it makes equipment for manufacturing semiconductor chips. Its specialty is ion implantation. Block Inc. (NYSE:XYZ) operates the Square payments system. Small businesses like its hardware and software, and it's been growing nicely. Profits have shot up at a 30% annual rate the past five years. Cactus Inc. (NYSE:WHD), which makes oil-drilling equipment, is based in (where else?) Houston, Texas. I particularly like its balance sheet, with debt only 4 percent of stockholders' equity. Cigna Group (NYSE:CI), one of the largest U.S. health insurers, has been a stodgy stock. But I think it would hold up well if the market turns rocky. Analysts expect earnings to rise. Crocs Inc. (NASDAQ:CROX) makes casual shoes with holes for ventilation or decoration. It was a fad stock several years ago, rising 104% from mid-2006 to the end of 2007. Now it seems attractively cheap to me at six times earnings. Disclosure: I own D.R. Horton for one client. John Dorfman is chairman of Dorfman Value Investments LLC in Boston, Massachusetts, and a syndicated columnist. His firm or clients may own or trade securities discussed in this column. He can be reached at jdorfman@ This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
Why Shopify Stock Is Rising Today
Key Points Investors may be responding to the fact that the E.U. said it won't increase tariffs on the U.S. just yet. But slowing job growth and uncertainty around tariffs could eventually weigh on the economy. Shopify investors should keep a close watch on the company's upcoming quarterly results. 10 stocks we like better than Shopify › Shares of the e-commerce platform company Shopify (NASDAQ: SHOP) were rebounding today after stumbling on Friday after a weaker-than-expected jobs report. Investors regained some of their optimism for the company today, as the European Union says it's delaying some retaliatory tariffs on the U.S. for six months. Shopify investors are closely watching for any positive economic news as they prepare for the company's Q2 earnings report due out on Wednesday. Shopify stock was up by more than 5% this morning and had gained 4.8% as of 11:29 a.m. ET. Some positive news ahead of Shopify's upcoming earnings report Profit growth has been slowing for Shopify, and investors will get more details on which direction it's currently headed when the company reports second-quarter results on Wednesday. In the meantime, investors were responding positively to the E.U.'s announcement that it will hold off on any retaliatory tariffs against the U.S., as it tries to strike a trade deal. Investors were spooked on Friday by a weak jobs report for June and significantly revised jobs numbers for May, which caused a sell-off among many stocks on Friday. So any news that the U.S. isn't entering a new stage of a trade war with the E.U. caused investors to respond positively. Shopify's growth is dependent on how well companies are growing in the U.S. and how many new businesses are started. So any slowdown in the economy will weigh down the company's sales and earnings. The latest job data wasn't a good sign, but with today's gains, it appears investors aren't yet sold on the idea that the U.S. economy is slowing down. Shopify investors will know more very soon Wednesday's Q2 report will prove whether investors' optimism is misplaced or not. It's certainly not time to panic about the economy, but there are significant uncertainties right now as hiring slows down and the dust settles on new tariffs. It could take months for both to work their way through the economy, which means the next few quarters will be especially important to watch for Shopify investors. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool has a disclosure policy. Why Shopify Stock Is Rising Today was originally published by The Motley Fool
Yahoo
a minute ago
- Yahoo
Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033
Innovation now defines the organ care products market. Advanced perfusion and portable systems are actively expanding the donor organ pool, tackling immense waiting lists driven by chronic diseases and dramatically improving success rates for vital transplants. Chicago, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global organ care products market was valued at US$ 199.20 million in 2024 and is expected to reach US$ 812.12 million by 2033, growing at a CAGR of 16.90% during the forecast period 2025–2033. The current scenario in the organ care products market is one of explosive growth, fueled by the twin engines of unprecedented global demand and transformative technology. In 2024, the U.S. performed a record 48,149 transplants, yet this barely meets the need, as regions like Eurotransplant still have over 13,570 patients on waiting lists. This profound supply-demand imbalance is accelerating a fundamental shift away from traditional static cold storage towards advanced perfusion and assessment systems. These technologies are directly addressing the critical issue of organ non-utilization, aiming to convert a portion of the thousands of organs discarded annually into life-saving opportunities, thereby changing the entire calculus of transplantation. Request Sample Pages: This evolution is being aggressively capitalized upon by key industry players through strategic expansion and is buoyed by substantial investment. Recent developments, such as Paragonix's EU MDR certification for five devices in March 2025 and its rapid U.S. commercial expansion, highlight a fierce race to capture market share. The market's momentum is further underwritten by significant capital influx, from government initiatives like the $67 million allocated for U.S. transplant system modernization in FY2025 to targeted research funding from organizations like Enduring Hearts. The current scenario is therefore not just about growth, but about a well-funded, strategic push to commercialize innovation on a global scale. Key Findings in Organ Care Products Market Market Forecast (2033) US$ 812.12 million CAGR 16.90% Largest Region (2024) North America (56%) By Organ Type Kidney (28%) By Product Type Trolly (53%) Top Drivers Rising global incidence of chronic diseases fuels organ transplant demand. Technological advancements in organ preservation systems improve transplant success rates. Favorable reimbursement policies encourage organ transplant procedures, boosting market growth. Top Trends Emergence of normothermic machine perfusion for real-time organ function assessment. Development of smaller, portable organ preservation devices for easier transport. Focus on developing organ-specific preservation solutions for better patient outcomes. Top Challenges Complex ethical and logistical hurdles in organ procurement and allocation. Unprecedented Transplant Volumes Are Fueling Robust Market Expansion and Demand The foundational driver for the organ care products market is the sheer volume of surgical procedures, which continued its upward trajectory through 2024. In the United States alone, a record of over 48,000 organ transplants were performed. This milestone was confirmed with a final tally of 48,149 procedures for the year, marking the first time the nation has exceeded this figure. This represents an impressive average of 132 organ transplants performed each day in the U.S. throughout 2024. Critically, 2024 marked the 14th consecutive year of growth in the number of organs recovered for transplants in the U.S., signaling a sustained and reliable increase in the core activity that underpins the market. This trend is not isolated; globally, organ transplantation activities saw a notable increase in 2023, which has set a strong precedent for continued growth in 2024 and beyond. In Europe, the eight Eurotransplant countries allocated 7,150 organs from deceased donors in 2024, while in China, a remarkable 24,684 transplant surgeries were performed during the same year, showcasing the truly global nature of this expansion. The Critical Role of Organ Procurement in Shaping Market Dynamics The availability and procurement of donor organs represent the starting point for the entire transplantation value chain, directly influencing the organ care products market. In the United States, 55 dedicated organ procurement organizations (OPOs) were operational as of October 2024, forming the backbone of the recovery network. In 2024, these U.S. OPOs successfully recovered over 45,000 organs for transplant procedures. This was made possible by the 16,989 Americans who became deceased organ donors, a testament to growing awareness and consent. These efforts were supplemented by more than 7,000 living donors in the U.S. in 2024. An interesting demographic trend shows that nearly 8,200 of the deceased donors in the U.S. in 2024 were aged 55 and older, highlighting the expanding criteria for donation. In the United Kingdom, from April 2023 to March 2024, there were 1,510 deceased organ donors and 938 living organ donors. Across the Eurotransplant region, organs were sourced from 2,181 deceased donors in 2024. Meanwhile, China recorded 6,744 cases of organ donations in 2024, with the number of registered organ donors soaring to over 7.05 million by early 2025, indicating massive future potential. Organ-Specific Procedural Growth Creates Niche Opportunities Within the Market A deeper analysis of procedural data reveals that growth is not uniform across all organ types, creating distinct and lucrative opportunities within the organ care products market for specialized preservation technologies. In the United States during 2024, cardiac procedures were significant, with 4,572 heart transplants performed. Thoracic procedures were also prominent, as the number of lung transplants reached 3,340. Abdominal transplants, which constitute the largest segment, saw a total of 11,458 liver transplants and an impressive 27,759 kidney transplants performed in the U.S. in 2024. This high volume in renal transplantation underscores the demand for reliable kidney preservation solutions. Furthermore, specialized procedures are gaining traction; in the UK, for instance, 65 Donation after Circulatory Death (DCD) heart transplants took place in the 2023/24 period, a complex procedure that relies heavily on advanced preservation technology to ensure viability. Diverse Regional Landscapes Present Unique Challenges and Growth Avenues The global organ care products market is characterized by significant regional variations in infrastructure, regulatory frameworks, and donation patterns. China's market, for example, is notable for its scale; as of early 2025, there have been more than 58,000 cumulative organ donations to date. The country has also recorded over 63,000 body donations and 110,000 corneal donations as of 2025, pointing to a well-established and growing donation culture. In the UK, the data from 2023-2024 provides a detailed look at the procurement funnel, with 772 donors after brain death (DBD) and 738 donors after circulatory death (DCD). That year, there were 6,794 potential deceased organ donors identified in the UK, of whom 6,421 were formally referred as potential donors. From that pool, donation requests were made to families in 3,107 cases, ultimately resulting in 1,880 consented donors, illustrating the multi-step process where advanced care technology can play a role in boosting confidence and consent. Groundbreaking Product Innovation and Regulatory Wins Propel Market Leaders Forward Innovation is the lifeblood of the organ care products market, with regulatory approvals serving as key milestones that unlock new commercial opportunities. In October 2024, Paragonix Technologies achieved a major milestone with FDA 510(k) clearance for its KidneyVault portable renal perfusion system. This strategic clearance solidified Paragonix as the only company possessing U.S. regulatory clearances for advanced preservation devices for all five solid organs used in transplants. Earlier in the year, in June 2024, the company launched its PancreasPak, the world's first FDA-cleared preservation device for donor pancreases, with pre-orders beginning on June 27, 2024, and full commercial availability planned for September 1, 2024. In April 2024, Paragonix also announced the full U.S. commercial launch of its BAROguard Donor Lung Preservation System. During its limited market release, 5 of the top U.S. thoracic transplant centers had already deployed the BAROguard System. The momentum continued into 2025, when Paragonix received EU MDR approval for five of its organ preservation devices in March. These specific product approvals stood out in a year where the FDA approved a total of just 21 medical devices overall in 2024. Strong Financial Performance and Strategic Investments Signal a Healthy Marketplace The financial health and strategic initiatives of key industry players in the organ care products market provide compelling evidence of a vibrant and growing market. XVIVO Perfusion reported strong results for 2024, with net sales amounting to SEK 822.4 million for the full year. The fourth quarter of 2024 was particularly robust, with net sales reaching SEK 227.6 million. The company's profitability was also solid, with an operating income (EBIT) for Q4 2024 of SEK 15.5 million and an operating income before depreciation and amortization (EBITDA) of SEK 51.9 million. Strong operational execution led to a cash flow from operating activities of SEK 62.1 million in Q4 2024, and the company posted a net profit for the full year 2024 of SEK 172.2 million. On the utilization front, Paragonix preservation devices have been used in over 10,000 transplant cases globally as of March 2025, demonstrating deep market penetration. Specifically, the Paragonix SherpaPak and LUNGguard systems are utilized at over 150 transplant centers globally, including over 40 transplant centers in the EU, highlighting the company's expanding international footprint. Modernization Initiatives and Research Funding Pave the Way for Future Growth Substantial government and institutional investments in research and system modernization are creating a fertile ground for the future growth of the organ care products market. The U.S. Senate Appropriations Committee has included a significant $67 million in funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative for fiscal year 2025. This represents a $13 million increase over FY 2024 levels. The FY24 funding package had already included an additional $23 Million for the HRSA OPTN Modernization Initiative, bringing the total for that year to $52 Million. In 2024, the Mid-America Transplant Foundation's Clinical Innovation Fund began offering awards of up to $150,000 per year for three years to spur new research. The American Society of Transplantation (AST) is furthering this by offering a research grant of $75,000 for one year, with a term starting January 1, 2025. The International Society for Heart & Lung Transplantation is offering a grant of up to $75,000 for research into DCD heart transplantation, with recipients to be announced in January 2025, and a second grant of up to $37,500 for acellular Ex Vivo Lung Perfusion (EVLP) research. In 2024, the Scandiatransplant Research grant also supported two projects with 100,630 DKK and 260,000 DKK, respectively. Need a Customized Version? Request It Now: Addressing Organ Utilization and Waiting Lists Remains a Core Market Imperative The persistent challenges of organ non-utilization and extensive patient waiting lists serve as powerful catalysts for the organ care products market, driving the need for technologies that can preserve, assess, and improve marginal organs. In 2024, a concerning 9,275 recovered kidneys in the U.S. were ultimately not used for transplant, continuing a trend that highlights a critical gap between recovery and utilization. To combat this, OPOs have hosted eleven Transplant Growth Collaborations over the past year to share successful practices. Advanced perfusion is emerging as a key solution; a 2024 study of 803 transplantations, of which 174 received Normothermic Machine Perfusion (NMP), showed NMP was associated with a reduced need for early relaparotomy in liver transplants. Another 2024 study involving 118 NMP-treated livers matched with 236 preserved with static cold storage, and a cohort matching 37 NMP-DCD livers with 74 using static cold storage, are providing crucial data on efficacy. Global Organ Care Products Market Major Players: Bridge to Life Ltd. TransMedics Inc. Organ Recovery system XVIVO Preservation Solution Inc. Paragonix technologies and IGL OrganOx Limited Other Prominent Players Key Market Segmentation: By Organ Type Kidney Liver Heart Lungs Others By Product Type Trolly Portable By Region North America Europe Asia Pacific Middle East Africa South America Request a Personalized Report Walkthrough with Our Research Team: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
